Jiayu Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiayu Zhang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Weize Xu
Heart Center Children's Hospital Zhejiang University School of Medicine National Clinical Research Center for Child Health Hangzhou China
2 shared publications - Die Li
Department of Epidemiology and Health Statistics, Zhejiang University School of Public Health, Hangzhou, China
1 shared publication - Dingfeng Wu
Department of Gynecology, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 200092, People’s Republic of China
1 shared publication - Qiang Shu
National Clinical Research Center for Child Health, Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication Rulai Yang
Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health
1 shared publicationWei Jiang
1 shared publication
Latest Publications
- Open Access
- 30 September 2025
- Published by BMJ in World Journal of Pediatric Surgery
- Vol. 8 (4) , e001107
Transthoracic pulmonary valve replacement for severe pulmonary regurgitation following pulmonary atresia repair with an intact ventricular septum: a case report
Pulmonary atresia with an intact ventricular septum (PA/IVS) is a rare congenital heart disease. Pulmonary regurgitation is a major late postsurgical complication and pulmonary valve replacement is the mainstream treatment. We report the case of a 15-year-old boy with PA/IVS who developed severe pulmonary regurgitation after prior surgical repair. Intraoperative angiography revealed the absence of bilateral femoral venous trunks, making transcatheter pulmonary valve replacement (TPVR) not feasible. Transthoracic pulmonary valve replacement using a self-expanding Venus P-Valve was successfully performed. Postoperative recovery was uneventful, and follow-up showed good valve function and improved right ventricular performance. Transthoracic implantation of a self-expanding pulmonary valve may serve as a safe and feasible alternative for patients with severe pulmonary regurgitation who are unsuitable for TPVR due to unfavorable vascular anatomy.
- 30 September 2025
- Published by BMJ in World Journal of Pediatric Surgery
- Vol. 8 (4) , e001107
Open AccessTransthoracic pulmonary valve replacement for severe pulmonary regurgitation following pulmonary atresia repair with an intact ventricular septum: a case report
Pulmonary atresia with an intact ventricular septum (PA/IVS) is a rare congenital heart disease. Pulmonary regurgitation is a major late postsurgical complication and pulmonary valve replacement is the mainstream treatment. We report the case of a 15-year-old boy with PA/IVS who developed severe pulmonary regurgitation after prior surgical repair. Intraoperative angiography revealed the absence of bilateral femoral venous trunks, making transcatheter pulmonary valve replacement (TPVR) not feasible. Transthoracic pulmonary valve replacement using a self-expanding Venus P-Valve was successfully performed. Postoperative recovery was uneventful, and follow-up showed good valve function and improved right ventricular performance. Transthoracic implantation of a self-expanding pulmonary valve may serve as a safe and feasible alternative for patients with severe pulmonary regurgitation who are unsuitable for TPVR due to unfavorable vascular anatomy.
- Open Access
- 6 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (9) , e039500
Resolving Early Targets and Metabolomic Profile of Congenital Heart Disease Through Tandem Mass Spectrometry Screening in Neonates
Background: A good prognosis of congenital heart disease (CHD) depends on early diagnosis and intervention. Under the current screening conditions, a significant proportion still go undetected. Metabolomics, as a phenotype‐correlated research methodology, remains underused in the study of CHD, which could provide the possibility to screen neonatal CHD efficiently. Methods: Data for the analysis are from >22 000 neonates captured in the Network Platform for CHD from April 2020 to November 2021 in 11 cities in China. After data matching and quality control, a total of 22 674 neonates were finally included and divided into the CHD group (n=1823), nonsignificant CHD group (n=17 968), and normal group (n=2748). Demographic and clinical characteristics and tandem mass spectrometry‐based metabolic data for genetic and metabolic disease screening were gathered and compared for all groups. Machine learning models based on metabolic biomarkers were constructed to screen CHD in neonates. Results: After quality control, 22 539 neonates were ultimately included. Among them, 1823 were diagnosed with CHD, 17 968 were nonsignificant CHD, and 2748 were normal. A total of 46 distinguishing metabolic biomarkers were identified, and we found that the CHD group had significantly lower levels of 17‐hydroxyprogesterone (CHD versus nonsignificant CHD, P 2 fold change=−0.16; CHD versus normal, P 2 fold change=−0.15). We constructed CHD and ventricular septal disease screening models based on metabolic biomarkers. The best fitting model achieved an area under the receiver operating characteristic curve of 0.745 (95% CI, 0.696–0.791). Conclusions: This study reveals the unique metabolic profile of neonates with CHD. The screening model demonstrates considerable potential in early neonatal CHD screening and reflects significant value from a health economics perspective.
- 6 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (9) , e039500
Open AccessResolving Early Targets and Metabolomic Profile of Congenital Heart Disease Through Tandem Mass Spectrometry Screening in Neonates
Background: A good prognosis of congenital heart disease (CHD) depends on early diagnosis and intervention. Under the current screening conditions, a significant proportion still go undetected. Metabolomics, as a phenotype‐correlated research methodology, remains underused in the study of CHD, which could provide the possibility to screen neonatal CHD efficiently. Methods: Data for the analysis are from >22 000 neonates captured in the Network Platform for CHD from April 2020 to November 2021 in 11 cities in China. After data matching and quality control, a total of 22 674 neonates were finally included and divided into the CHD group (n=1823), nonsignificant CHD group (n=17 968), and normal group (n=2748). Demographic and clinical characteristics and tandem mass spectrometry‐based metabolic data for genetic and metabolic disease screening were gathered and compared for all groups. Machine learning models based on metabolic biomarkers were constructed to screen CHD in neonates. Results: After quality control, 22 539 neonates were ultimately included. Among them, 1823 were diagnosed with CHD, 17 968 were nonsignificant CHD, and 2748 were normal. A total of 46 distinguishing metabolic biomarkers were identified, and we found that the CHD group had significantly lower levels of 17‐hydroxyprogesterone (CHD versus nonsignificant CHD, P 2 fold change=−0.16; CHD versus normal, P 2 fold change=−0.15). We constructed CHD and ventricular septal disease screening models based on metabolic biomarkers. The best fitting model achieved an area under the receiver operating characteristic curve of 0.745 (95% CI, 0.696–0.791). Conclusions: This study reveals the unique metabolic profile of neonates with CHD. The screening model demonstrates considerable potential in early neonatal CHD screening and reflects significant value from a health economics perspective.